Relay Therapeutics (RLAY) Cash & Equivalents (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash & Equivalents data on file, last reported at $204.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $204.6 million, up 118.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $204.6 million (up 118.71% YoY), and the FY2025 annual result was $84.0 million, down 32.4% from the prior year.
• Cash & Equivalents climbed to $204.6 million in Q1 2026 per RLAY's latest filing, from $84.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $354.6 million in Q3 2022 and troughed at $84.0 million in Q4 2025.
• A 5-year average of $146.3 million and a median of $143.7 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents slumped 58.57% in 2022, then surged 118.71% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $151.8 million in 2022, then retreated by 5.31% to $143.7 million in 2023, then declined by 13.53% to $124.3 million in 2024, then sank by 32.4% to $84.0 million in 2025, then surged by 143.51% to $204.6 million in 2026.
• Business Quant data shows RLAY's Cash & Equivalents at $204.6 million in Q1 2026, $84.0 million in Q4 2025, and $91.6 million in Q3 2025.